NEW YORK (GenomeWeb News) – The molecular diagnostics company AMDL said today that it has licensed a human papillomavirus diagnostic genotyping test from MyGene International for use in Asia.
Under the exclusive sublicense agreement, AMDL will use MyGene’s HPV Chip Kit patents to make, market, sell, and distribute the MyGene HPV Test Kit in China, Taiwan, Singapore, Malaysia, Thailand, Cambodia, and Vietnam.
AMDL is based in Tustin, Calif., but also has operations in three cities in China. The company’s Chinese branch is run through its subsidiary, Jade Pharmaceutical International.
AMDL said an “extremely conservative” estimate for a market for HPV testing in China could be around $50 million. The company also said that there are around 330 million women infected with HPV in the world, and that 70 percent of the existing infections are in Asian populations.
Financial terms of the agreement were not released.